Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative Radiotherapy Plus Anti-PD-1 Maintenance in NSCLC
NCT07353476Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2026
- Primary completion
- Jun 2030
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Disease-Free Survival at 3 years. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07353476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353476.